{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T09:45:33Z","timestamp":1775641533530,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T00:00:00Z","timestamp":1582502400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T00:00:00Z","timestamp":1582502400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s10384-019-00708-0","type":"journal-article","created":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T12:06:58Z","timestamp":1582546018000},"page":"103-113","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A scoping review and network meta-analysis for efficacy and safety of glaucoma medication in Japanese patients"],"prefix":"10.1007","volume":"64","author":[{"given":"Kenji","family":"Inoue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goji","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Noma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,24]]},"reference":[{"key":"708_CR1","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S0002-9394(98)00272-4","volume":"126","author":"Collaborative Normal-tension Glaucoma Study Group","year":"1998","unstructured":"Collaborative Normal-tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998;126:498\u2013505.","journal-title":"Am J Ophthalmol."},{"key":"708_CR2","unstructured":"Guidelines for the clinical management of glaucoma. Nippon Ganka Gakkai Zasshi. 2018;122:5\u201353 (in Japanese)."},{"key":"708_CR3","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.ophtha.2005.01.042","volume":"112","author":"R van der Volk","year":"2005","unstructured":"van der Volk R, Webers CA, Schouten JS, Zeegers MP, Hendrikse F, Prins MH. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology. 2005;112:1177\u201385.","journal-title":"Ophthalmology."},{"key":"708_CR4","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1442-9071.2008.01720.x","volume":"36","author":"SC Loon","year":"2008","unstructured":"Loon SC, Liew G, Fung A, Reid SE, Craig JC. Meta-analysis of randomized controlled trials comparing timolol with brimonidine in the treatment of glaucoma. Clin Exp Ophthalmol. 2008;36:281\u20139.","journal-title":"Clin Exp Ophthalmol."},{"key":"708_CR5","first-page":"447","volume":"3","author":"O Eyawo","year":"2009","unstructured":"Eyawo O, Nachega J, Lefebvre P, Meyer D, Rachlis B, Lee CW, et al. Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis. Clin Ophthalmol. 2009;3:447\u201356.","journal-title":"Clin Ophthalmol."},{"key":"708_CR6","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.curtheres.2009.08.006","volume":"70","author":"JW Cheng","year":"2009","unstructured":"Cheng JW, Xi GL, Wei RL, Cai JP, Li Y. Effects of travoprost in the treatment of open-angle glaucoma or ocular hypertension: a systematic review and meta-analysis. Curr Ther Res Clin Exp. 2009;70:335\u201350.","journal-title":"Curr Ther Res Clin Exp."},{"key":"708_CR7","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","volume":"331","author":"DM Caldwell","year":"2005","unstructured":"Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005;331:897\u2013900.","journal-title":"BMJ."},{"key":"708_CR8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.1037","volume":"3","author":"G Salanti","year":"2012","unstructured":"Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods. 2012;3:80\u201397.","journal-title":"Res Synth Methods."},{"key":"708_CR9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ophtha.2015.09.005","volume":"123","author":"T Li","year":"2016","unstructured":"Li T, Lindsley K, Rouse B, Hong H, Shi Q, Friedman DS, et al. Comparative effectiveness of first-line medications for primary open-angle glaucoma\u2014a systematic review and network meta-analysis. Ophthalmology. 2016;123:129\u201340.","journal-title":"Ophthalmology."},{"key":"708_CR10","doi-asserted-by":"publisher","first-page":"e277","DOI":"10.1111\/aos.13568","volume":"96","author":"F Li","year":"2018","unstructured":"Li F, Huang W, Zhang X. Efficacy and safety of different regimens for primary open-angle glaucoma or ocular hypertension: a systematic review and network meta-analysis. Acta Ophthalmol. 2018;96:e277\u201384.","journal-title":"Acta Ophthalmol."},{"key":"708_CR11","first-page":"607","volume":"90","author":"H Mishima","year":"1996","unstructured":"Mishima H, Masuda K, Araie M, Kitazawa Y, Shiose Y, Azuma I, et al. Phase III clinical study on PhXA41 ophthalmic solution on primary open angle glaucoma and ocular hypertension. A multicenter, double-blind comparison with 0.5% maleate. Ganka Rinsho Iho. 1996;90:607\u201315 (in Japanese).","journal-title":"Ganka Rinsho Iho."},{"key":"708_CR12","unstructured":"Common technical document of travoprost for the drug approval application in Japan. Study Number C025."},{"key":"708_CR13","first-page":"1595","volume":"25","author":"Y Kuwayama","year":"2008","unstructured":"Kuwayama Y, Komemushi S. Phase III confirmatory study of 0.0015% DE-085 (tafluprost) ophthalmic solution as compared to 0.005% latanoprost ophthalmic solution in patients with open-angle glaucoma or ocular hypertension. Atarashi Ganka. 2008;25:1595\u2013602 (in Japanese).","journal-title":"Atarashi Ganka."},{"key":"708_CR14","unstructured":"Common technical document of bimatoprost for the drug approval application in Japan. Study Number 904."},{"key":"708_CR15","unstructured":"Common technical document of bimatoprost for the drug approval application in Japan. Study Number 3-03."},{"key":"708_CR16","first-page":"1432","volume":"43","author":"I Azuma","year":"1992","unstructured":"Azuma I, Masuda K, Kitazawa Y, Takase M, Yamamura H. Phase III double masked comparative study of UF-021 ophthalmic solution in primary open-angle glaucoma and ocular hypertention. Nihon Ganka Kiyo. 1992;43:1432\u201340 (in Japanese).","journal-title":"Nihon Ganka Kiyo."},{"key":"708_CR17","unstructured":"Common technical document of brimonidine tartrate for the drug approval application in Japan. Study Number 3-02."},{"key":"708_CR18","first-page":"143","volume":"13","author":"Y Kitazawa","year":"1996","unstructured":"Kitazawa Y, Azuma I, Tsukahara S, Komemushi S. Clinical evaluation of timolol GS once-a-day ophthalmic solution in primary open-angle glaucoma and ocular hypertension -phase III comparative study with timolol twice-a-day ophthalmic solution as control drug-. Atarashi Ganka. 1996;13:143\u201354 (in Japanese).","journal-title":"Atarashi Ganka."},{"key":"708_CR19","first-page":"1771","volume":"13","author":"K Masuda","year":"1996","unstructured":"Masuda K, Takase M, Kitazawa Y, Shiose Y, Azuma I, Ogawa N, et al. Phase III comparative clinical study on KT-210 in patients with primary open-angle glaucoma and ocular hypertension -multicenter cooperative between-group comparative double-blind clinical trial with 0.5% timolol meleate ophthalmic solution. Atarashi Ganka. 1996;13:1771\u201383 (in Japanese).","journal-title":"Atarashi Ganka."},{"key":"708_CR20","first-page":"1280","volume":"88","author":"I Azuma","year":"1994","unstructured":"Azuma I, Kitazawa Y, Tsukahara S, Takase M, Shiose Y, Komemushi S. Phase III clinical trial of bunazosin hydrochloride ophthalmic solution for primary open angle glaucoma and ocular hypertension. A multicenter double-masked comparative study using 0.5% timolol maleate ophthalmic solution. Ganka Rinsho Iho. 1994;88:1280\u20135 (in Japanese).","journal-title":"Ganka Rinsho Iho."},{"key":"708_CR21","first-page":"2683","volume":"12","author":"Y Kitazawa","year":"1996","unstructured":"Kitazawa Y, Tsukahara S, Azuma I, Abe H, Mishima H, Negi A, et al. Clinical evaluation of WP-934 ophthalmic solution in primary open-angle glaucoma and ocular hypertension\u2014phase III comparative study with timoptol ophthalmic solution as control drug-. Rinsho Iyaku. 1996;12:2683\u2013701 (in Japanese).","journal-title":"Rinsho Iyaku."},{"key":"708_CR22","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1177\/0962280207080643","volume":"17","author":"G Salanti","year":"2008","unstructured":"Salanti G, Higgins JP, Ades AE, Loanidis JP. Evaluation of networks of randomized trials. Stat Methods Med Res. 2008;17:279\u2013301.","journal-title":"Stat Methods Med Res."},{"key":"708_CR23","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777\u201384.","journal-title":"Ann Intern Med."},{"key":"708_CR24","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","volume":"50","author":"HC Bucher","year":"1997","unstructured":"Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50:683\u201391.","journal-title":"J Clin Epidemiol."},{"key":"708_CR25","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/jrsm.1044","volume":"3","author":"JP Higgins","year":"2012","unstructured":"Higgins JP, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods. 2012;3:98\u2013110.","journal-title":"Res Synth Methods."}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-019-00708-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10384-019-00708-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-019-00708-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T00:39:54Z","timestamp":1614040794000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10384-019-00708-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,24]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["708"],"URL":"https:\/\/doi.org\/10.1007\/s10384-019-00708-0","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,24]]},"assertion":[{"value":"11 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K Inoue, Grant (Santen, Alcon, Senju, Allergan Japan, Teijin, QVIA Services JAPAN, Mayo, Eli Lilly Japan), Lecture fee (Santen, Otsuka, Senju Pharmaceutical, Kowa Pharmaceutical, Allergan Japan, Novartis, Wakamoto), Writing fee (Santen), Consultant fee (Santen); K. Ishida, Lecture fee (Alcon, Pfizer, Santen, Senju, Otsuka, Kowa Pharmaceutical, AMO, Sucampo, GlaxoSmithKline, JFC Sales Plan); G. Tomita, Grant (Alcon, Pfizer, Santen, Senju, TOPCON, Handaya, Kowa, Otsuka, AMO Japan), Lecture fee (Pfizer, Santen, Senju, Otsuka, Japan Focus Company), Consultant fee (Allergan Japan); H. Noma, Lecture fee (Nippon Boehringer Ingelheim, Kyowa Hakko Kirin, ASKA).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}